Cancer caregivers in emerging and young adulthood (ages 18-35) are an underresearched and unsupported group of caregivers, and yet they are not uncommon. To address this critical support gap, the goal of this study is to develop and pilot test a caregiving support intervention specifically tailored for emerging and young adults caring for a parent with cancer. This phase of the study is intended to capture feedback on the intervention via focus groups with emerging and young adult caregivers of a parent with cancer.

The goal is to evaluate how well etrasimod helps reduce symptoms by week 12 of treatment. This involves determining whether patients experience enough improvement to be considered in remission. The focus is on how the medication performs in everyday, real-world conditions.

The purpose of this research is to assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.

A germ (bacterium) called meningococcus, or Neisseria meningitidis, can cause several serious diseases, including meningitis and blood infection. Meningitis affects the brain and spinal cord. It can cause hearing loss, seizures, learning and behavior problems, severe brain damage and even death. Meningitis can happen to anyone but is more common in teenagers and young children, including babies. This research study will help us learn about vaccines that protect against diseases caused by different types of meningococcus germs: types A, B, C, W, Y.

This study is being conducted to learn more about the safety and immune response of the study vaccine MenABCWY when 2 doses are given 24 months apart (0,24-month schedule) or 48 months apart (0,48-month schedule). The study will be conducted in healthy adolescents from 11 to 14 years of age.

The purpose of this study is evaluate safety and effectiveness of an investigational drug in adults diagnosed with chronic urticaria (hives). The investigational drug is known as BLU-808 and will be taken daily orally. Participation in the study is expected to be approximately 18 weeks.

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.

This is a Phase 3 study. Phase 3 studies can involve testing a study drug in hundreds to thousands of people over several years. The main purpose of this study is to see if the study drug, Niraparib, works better than the comparator drug in people who have just been diagnosed with glioblastoma. The comparator drug is a type of chemotherapy commonly used to treat newly diagnosed glioblastoma.
This study includes:
• Phase 1, where subjects will take either the study drug or comparator drug. All participants will also receive radiotherapy in this phase. In this phase, there will be about 45 visits to the study center. The duration for this phase will last as long as the cancer does not get worse.
• Phase 2, where subjects will continue with the same drug given in Phase 1 without radiotherapy. In this phase there will be about 53 visits to the study center and participation in the study will last for 42 weeks.
There are four periods of the study, the screening period (last about 1 month), study treatment period (as long as desired or up to 8 months), safety follow-up period (1 month), and long-term follow up period (up to 5 years).
Some procedures in this study are blood tests, memory, speech and thinking test, ECG, tissue sample, bone marrow biopsy, and imaging test. Some risks include the cancer could get worse and there are risks associated with the study drugs (for example, low appetite, difficulty speaking, headaches, vomiting, nausea, diarrhea, etc.)

This study is for adult patients with large brain metastases. The purpose of this study is to compare two different radiation therapy dose treatments: staged stereotactic radiosurgery (SSRS) and fractionated stereotactic radiotherapy (FSRT). Both treatment options are currently used as standard of care. Participation in this study will include standard of care visits along with questionnaires completed for research purposes.

Deep brain stimulation (DBS) is a surgical treatment that can help improve the symptoms of Parkinson's disease (PD). However, the effectiveness of this treatment varies among patients, and physicians currently have no way to predict who will benefit the most. This study will investigate whether the types of bacteria in a person's gut can help predict their response to DBS. By analyzing patient samples, we aim to identify biomarkers that could help doctors better select candidates for this procedure, ultimately leading to more successful treatment outcomes for individuals with Parkinson's disease.

This study is a non-interventional, multicenter investigation of patient outcomes, combining a retrospective medical chart review with prospective patient questionnaires. It focuses on patients receiving ritlecitinib, baricitinib, or standard of care (SOC) treatment for alopecia areata (AA). Prospective data will be collected over 12 months following the start of treatment. The study aims to enroll 300 adults (aged 18 and older) and 100 adolescents/minors (aged 12-17) from 20-25 sites across the USA. Among the adult participants, 100 will receive ritlecitinib, 100 baricitinib, and 100 SOC. The adolescent/minor group will include 50 receiving ritlecitinib and 50 SOC.